# platinum-resistant ovarian cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/platinum-resistant-ovarian-cancer

> 4 upcoming FDA catalysts in platinum-resistant ovarian cancer: N-803 (IBRX) on May 2027 (primary completion); N-803 (IBRX) on May to Aug 2027 (topline data readout); rina-s (GMAB) on September 2027 (primary completion); rina-s (GMAB) on Sep to Dec 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 10, 2025 | [Corcept NDA/BLA acceptance](https://sec-api.dev/pdufa/corcept) | CORT | platinum-resistant ovarian cancer | completed | "On September 10, 2025, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312525199706/d947259d8k.htm)) |
| July 11, 2026 | [Lifyorli™ (relacorilant) PDUFA date](https://sec-api.dev/pdufa/relacorilant) | CORT | platinum-resistant ovarian cancer | scheduled | ""Our NDA for relacorilant in platinum-resistant ovarian cancer, which is now bolstered by the final overall survival results from our ROSELLA study, has a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm)) |
| August 18, 2026 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-resistant Ovarian Cancer | completed | "NCT06619236 (Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619236)) |
| Aug to Nov 2026 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-resistant Ovarian Cancer | scheduled | "NCT06619236 (Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619236)) |
| October 23, 2026 | [Rinatabart topline data readout](https://sec-api.dev/pdufa/rinatabart) | GMAB | platinum-resistant ovarian cancer | completed, positive | "Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000138/gmab_20261023xex99d1.htm)) |
| May 2027 | [N-803 primary completion](https://sec-api.dev/pdufa/n-803) | IBRX | Platinum-resistant Ovarian Cancer | scheduled | "NCT06710288 (A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06710288)) |
| May to Aug 2027 | [N-803 topline data readout](https://sec-api.dev/pdufa/n-803) | IBRX | Platinum-resistant Ovarian Cancer | scheduled | "NCT06710288 (A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06710288)) |
| September 2027 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-resistant Ovarian Cancer | scheduled | "NCT07604766 (An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07604766)) |
| Sep to Dec 2027 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-resistant Ovarian Cancer | scheduled | "NCT07604766 (An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07604766)) |

## Drugs

- [Corcept](https://sec-api.dev/pdufa/corcept) (CORT)
- [Lifyorli™ (relacorilant)](https://sec-api.dev/pdufa/relacorilant) (CORT)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Rinatabart](https://sec-api.dev/pdufa/rinatabart) (GMAB)
- [N-803](https://sec-api.dev/pdufa/n-803) (IBRX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/platinum-resistant-ovarian-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "platinum-resistant ovarian cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/platinum-resistant-ovarian-cancer

```bibtex
@misc{secapidev_indications_platinum_resistant_ovarian_cancer_20261116,
  title        = {platinum-resistant ovarian cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/platinum-resistant-ovarian-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_platinum_resistant_ovarian_cancer_20261116","title":"platinum-resistant ovarian cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/platinum-resistant-ovarian-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
